Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/ZAI LAB LTD/ 10-Q

Quarterly Report · 10-Q

ZAI LAB LTD

ZAILFOTCEQUITYCurrent

Quarterly Report

Filed May 7, 2026Accepted May 7, 2026, 6:09 AM EDTCIK 1704292Accession 0001628280-26-031626
View company →Permanent SEC source ↗
Share

Company context

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.

Current securities

ZAILFOTC · EQUITY · CurrentZLABNASDAQ · ADR · Current

Recent company filings

  1. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure · Other EventsOct 23, 2026
  2. 4 filingAug 21, 2026
  3. 144 filingAug 19, 2026
  4. 4 filingAug 18, 2026
  5. 4 filingAug 13, 2026

Registered securities in this filing

ZAI LAB LIMITED · 10-Q · Filed 2026-05-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share

Symbol
ZLAB
Exchange
NASDAQ
Classification
ADS
Status
Current
Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

Ordinary Shares, par value $0.000006 per share

Symbol
9688
Exchange
Not supplied
Classification
COMMON
Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000162828026031626 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.